Across different drugs and clinical settings, use of PARPi has resulted in a prolonged period without cancer recurrence.
Kristin N. Taylor, MD
Advertisement
Articles by Kristin N. Taylor, MD
Across different drugs and clinical settings, use of PARPi has resulted in a prolonged period without cancer recurrence.
Advertisement
Latest Updated Articles
PARP inhibitors: Choosing what to use in epithelial ovarian cancerPublished: June 23rd 2020 | Updated:
PARP inhibitors: Choosing what to use in epithelial ovarian cancerPublished: April 7th 2020 | Updated:
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Criminalizing prenatal drug use linked to reduced prenatal care
2
Elisabet Stener-Victorin, PhD, highlights 4 unique PCOS subtypes for personalized care
3
AMH levels predict fertility treatment success in cancer patients
4
Prenatal COVID-19 exposure linked to adverse offspring neurodevelopment
5
